… in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
… to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology … s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA …
… to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …